Prognostic marker C3AR1 is associated with ovarian cancer cell proliferation and immunosuppression in the tumor microenvironment
暂无分享,去创建一个
[1] Antonios Revythis,et al. Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer , 2022, International journal of environmental research and public health.
[2] Aruni Ghose,et al. Applications of Proteomics in Ovarian Cancer: Dawn of a New Era , 2022, Proteomes.
[3] Sidrah Shah,et al. Non-Epithelial Ovarian Cancers: How Much Do We Really Know? , 2022, International journal of environmental research and public health.
[4] S. Harper,et al. Human miRNA miR-675 inhibits DUX4 expression and may be exploited as a potential treatment for Facioscapulohumeral muscular dystrophy , 2021, Nature Communications.
[5] C. Xiao,et al. Screening of CXC chemokines in the microenvironment of ovarian cancer and the biological function of CXCL10 , 2021, World Journal of Surgical Oncology.
[6] Mohamed H. Mahmoud,et al. Pan-Cancer Analysis of Immune Complement Signature C3/C5/C3AR1/C5AR1 in Association with Tumor Immune Evasion and Therapy Resistance , 2021, Cancers.
[7] Kun Huang,et al. C3AR1 mRNA as a Potential Therapeutic Target Associates With Clinical Outcomes and Tumor Microenvironment in Osteosarcoma , 2021, Frontiers in Medicine.
[8] Xiangliang Yang,et al. Boosting anti-PD-1 therapy with metformin-loaded macrophage-derived microparticles , 2021, Nature communications.
[9] S. Xia,et al. Dual inhibition of EGFR and IL-6-STAT3 signalling by miR-146b: a potential targeted therapy for epithelial ovarian cancer , 2021, Journal of enzyme inhibition and medicinal chemistry.
[10] Xiaoyu Liu,et al. High Expression of the Component 3a Receptor 1 (C3AR1) Gene in Stomach Adenocarcinomas Infers a Poor Prognosis and High Immune-Infiltration Levels , 2020, Medical science monitor : international medical journal of experimental and clinical research.
[11] Shibo Zhang,et al. Macrophage-mediated vascular permeability via VLA4/VCAM1 pathway dictates ascites development in ovarian cancer. , 2020, The Journal of clinical investigation.
[12] Zhiqiang Li,et al. C3, C3AR1, HLA-DRA, and HLA-E as potential prognostic biomarkers for renal clear cell carcinoma , 2020, Translational andrology and urology.
[13] Bao-qin Liu,et al. m6A-YTHDF1-mediated TRIM29 upregulation facilitates the stem cell-like phenotype of cisplatin-resistant ovarian cancer cells. , 2020, Biochimica et biophysica acta. Molecular cell research.
[14] G. Calin,et al. Bone morphogenetic protein 7 promotes resistance to immunotherapy , 2020, Nature Communications.
[15] Yufei Wang,et al. Targeting Myeloid-Derived Suppressor Cells in Cancer Immunotherapy , 2020, Cancers.
[16] Hong Yang,et al. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner , 2020, Theranostics.
[17] A. Martins Filho,et al. Serum cytokines and CXCR2: potential tumour markers in ovarian neoplasms , 2020, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.
[18] Qun Zhou,et al. Comprehensive landscape of extracellular vesicle-derived RNAs in cancer initiation, progression, metastasis and cancer immunology , 2020, Molecular Cancer.
[19] X. Ju,et al. A Novel Prognostic Marker Systemic Inflammation Response Index (SIRI) for Operable Cervical Cancer Patients , 2020, Frontiers in Oncology.
[20] Yuquan Zhang,et al. Cyclin H predicts the poor prognosis and promotes the proliferation of ovarian cancer , 2020, Cancer Cell International.
[21] C. Luo,et al. Estrogen enhances the proliferation and migration of ovarian cancer cells by activating transient receptor potential channel C3 , 2020, Journal of Ovarian Research.
[22] Fang Wang,et al. The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation , 2020, Nucleic acids research.
[23] K. Tucker,et al. Docosahexaenoic acid (DHA), an omega-3 fatty acid, inhibits tumor growth and metastatic potential of ovarian cancer. , 2020, American journal of cancer research.
[24] C. Shao,et al. Harnessing tumor-associated macrophages as aids for cancer immunotherapy , 2019, Molecular Cancer.
[25] L. Kwak,et al. Targeting myeloid-derived suppressor cells for cancer immunotherapy , 2018, Cancer Immunology, Immunotherapy.
[26] Yan Kang,et al. Tregs: Where We Are and What Comes Next? , 2017, Front. Immunol..
[27] Yi Luo,et al. Downregulation of LAPTM5 suppresses cell proliferation and viability inducing cell cycle arrest at G0/G1 phase of bladder cancer cells. , 2017, International journal of oncology.
[28] Hidde L. Ploegh,et al. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion , 2014, Nature.
[29] G. Weiner,et al. Complement in monoclonal antibody therapy of cancer , 2014, Immunologic research.
[30] K. Baggerly,et al. Autocrine Effects of Tumor-Derived Complement , 2014, Cell reports.
[31] Hilde van der Togt,et al. Publisher's Note , 2003, J. Netw. Comput. Appl..